Biotech, Cystic Fibrosis, Drugs
Vertex Starts Pivotal CF Trials
Luke Timmerman 5/27/09
Vertex Pharmaceuticals (NASDAQ: VRTX), the Cambridge, MA-based biotech company which has significant operations in San Diego, said today it has started a pivotal clinical trial program for its drug candidate for cystic fibrosis, a genetic lung disease. The company is running a series of three trials of VX-770, a drug that aims to be the first of its kind to target the defective protein that causes cystic fibrosis. The trials will aim to enroll 240 patients at 110 clinical trial sites in North America, Europe, and Australia.
Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.
5/27/09 9:47 am
[...] Vertex Starts Pivotal CF Trials | Xconomy Vertex, a Boston-based biotech with offices in San Diego, announces clinical trials of their new Cystic Fibrosis drug. It will be exciting to see how these go. Cystic Fibrosis, an abnormality to a protein that regulates chloride ions in cells, is one of the most common genetic conditions in our population, and often shows up in business models that monetize gene therapies with the potential to lead to personalized medicine. http://www.xconomy.com/boston/2009/05/27/vertex-starts-pivotal-cf-trials/ [...]
6/18/09 5:14 am
[...] Vertex Starts Pivotal CF Trials (xconomy.com) [...]